Mediwound Ltd
F:M8W

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
F:M8W
Watchlist
Price: 16 EUR 1.91% Market Closed
Market Cap: 148.5m EUR

M8W's latest stock split occurred on Dec 20, 2022

The company executed a 1-for-7 stock split, meaning that for every 7 shares held, investors received 1 new share.

Before the split, M8W traded at 1.25 per share. Afterward, the share price was about 7.95.

The adjusted shares began trading on Dec 20, 2022. This was the only stock split in M8W's history.

Last Splits:
Dec 20, 2022
1-for-7
Pre-Split Price
1.25 1.25
Post-Split Price
7.95
Before
After
Last Splits:
Dec 20, 2022
1-for-7

Mediwound Ltd
Stock Splits History

M8W Stock Splits Timeline
Dec 20, 2022
Dec 20, 2022
Split 1-for-7
/0.14285714285714
Pre-Split Price
1.25 1.25
Post-Split Price
7.95
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

Mediwound Ltd
Glance View

Market Cap
148.5m EUR
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

M8W Intrinsic Value
5.81 EUR
Overvaluation 64%
Intrinsic Value
Price
Back to Top